Summit Therapeutics PLC Company Profile (LON:SUMM)

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SUMM
  • CUSIP:
Key Metrics:
  • Previous Close: $2.37
  • 50 Day Moving Average: $170.81
  • 200 Day Moving Average: $152.87
  • 52-Week Range: £618,150 - GBX 82.66
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $117.45M
  • Outstanding Shares: 61,815,000
Additional Links:

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2017N+1 SingerReiterated RatingCorporateView Rating Details
4/2/2015JMP SecuritiesInitiated CoverageOutperformView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
Current Year EPS Consensus Estimate: $-38.45 EPS

Dividends

Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (LON:SUMM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
DateHeadline
News IconStock Price Target in Spotlight: Summit Therapeutics plc (:SMMT) - Rockville Register (LON:SUMM)
rockvilleregister.com - February 14 at 1:28 AM
lse.co.uk logoSUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES - London South East (registration) (blog) (LON:SUMM)
www.lse.co.uk - February 3 at 6:03 AM
streetinsider.com logoForm 6-K Summit Therapeutics plc For: Feb 01 - StreetInsider.com (LON:SUMM)
www.streetinsider.com - February 3 at 6:03 AM
marketexclusive.com logoWhat We're Looking For From Summit Therapeutics PLC (ADR ... - Market Exclusive (LON:SUMM)
marketexclusive.com - February 3 at 6:03 AM
capitalcube.com logoSummit Therapeutics Plc – Value Analysis (LONDON:SUMM) : January 24, 2017 (LON:SUMM)
www.capitalcube.com - January 25 at 6:19 AM
capitalcube.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : January 23, 2017 (LON:SUMM)
www.capitalcube.com - January 23 at 8:16 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Summit Therapeutics plc (:SMMT) - Wall Street Beacon (LON:SUMM)
wsbeacon.com - January 14 at 8:05 PM
capitalcube.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : January 12, 2017 (LON:SUMM)
www.capitalcube.com - January 12 at 11:13 PM
live-pr.com logoSummit Therapeutics Plc (SUMM) - Financial and Strategic SWOT Analysis Review - New Market Study Published (LON:SUMM)
www.live-pr.com - December 28 at 8:59 AM
capitalcube.com logoSummit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2016 (LON:SUMM)
www.capitalcube.com - December 22 at 3:22 AM
News IconMarket Scope: F-Score and Volatility Review for Summit Therapeutics plc (AIM:SUMM) - The Business Journal (LON:SUMM)
belmontbusinessjournal.com - December 20 at 7:56 PM
News IconMarket Corner: Eye on Technicals for Summit Therapeutics Plc (SMMT) - Yankee Analysts (LON:SUMM)
yankeeanalysts.com - December 16 at 5:07 AM
globenewswire.com logoSummit Therapeutics plc : 3rd Quarter Results - GlobeNewswire (press release) (LON:SUMM)
globenewswire.com - December 16 at 5:07 AM
biz.yahoo.com logoQ3 & 9M 2017 Summit Therapeutics PLC Earnings Release - Before Market Open (LON:SUMM)
biz.yahoo.com - December 16 at 5:07 AM
einnews.com logoA New Poll for 2020 Has Joe Biden in the Lead Among Democrats (LON:SUMM)
uspolitics.einnews.com - December 14 at 5:02 AM
finance.yahoo.com logoSummit Therapeutics plc : Notice of Results (LON:SUMM)
finance.yahoo.com - December 14 at 5:02 AM
sbwire.com logoFuture of Global Duchenne Muscular Dystrophy Treatment Market: Report Forecast 2016 to 2024 (LON:SUMM)
www.sbwire.com - December 8 at 12:54 AM
sbwire.com logoDuchenne Muscular Dystrophy Treatment Market Will Continue to Grow by 2024 (LON:SUMM)
www.sbwire.com - December 7 at 8:26 AM
News IconChecking the Metrics on Shares of Summit Therapeutics plc (AIM:SUMM) - The Business Journal (LON:SUMM)
belmontbusinessjournal.com - November 30 at 10:31 AM
News IconTracking the Numbers for Summit Therapeutics plc (AIM:SUMM) - The Business Journal (LON:SUMM)
belmontbusinessjournal.com - November 29 at 3:38 PM
capitalcube.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : November 23, 2016 (LON:SUMM)
www.capitalcube.com - November 23 at 10:57 AM
News IconSummit Therapeutics Plc SUMM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (LON:SUMM)
www.bioportfolio.com - November 22 at 7:52 PM
einnews.com logoNorth Korea makes first mention of US election result (LON:SUMM)
world.einnews.com - November 17 at 7:24 PM
investingnews.com logoSummit Enrolls US Patients into a Phase 2 Clinical Trial of Ezutromid (LON:SUMM)
investingnews.com - November 17 at 11:59 AM
trustnet.com logoSummit Enrolls Patients in the US into PhaseOut... (LON:SUMM)
www.trustnet.com - November 17 at 11:59 AM
4-traders.com logoSummit Therapeutics : Enrols First US Patients For Ezutromid Trial (LON:SUMM)
www.4-traders.com - November 17 at 11:59 AM
News IconQ3 2016 EPS Estimates for Sarepta Therapeutics Inc. Reduced by Wedbush (SRPT) (LON:SUMM)
larampadinapoli.com - October 7 at 11:20 AM
proactiveinvestors.co.uk logoSummit and Sarepta: The key questions answered (LON:SUMM)
www.proactiveinvestors.co.uk - October 7 at 11:20 AM
News IconSummit Therapeutics plc : Exercise of Options (LON:SUMM)
forextv.com - October 7 at 11:20 AM
News IconSarepta licenses Duchenne drug candidate from Summit (LON:SUMM)
myhealthbowl.com - October 6 at 7:15 PM
finance.yahoo.com logoSummit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society (LON:SUMM)
finance.yahoo.com - October 6 at 11:25 AM
finance.yahoo.com logoSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy (LON:SUMM)
finance.yahoo.com - October 4 at 11:04 AM
finance.yahoo.com logoSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy (LON:SUMM)
finance.yahoo.com - October 4 at 11:03 AM
uk.finance.yahoo.com logoBUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal (LON:SUMM)
uk.finance.yahoo.com - October 4 at 11:03 AM
4-traders.com logoSummit Therapeutics : Gets Rare Paediatric Disease Designation For Ezutromid (LON:SUMM)
www.4-traders.com - September 28 at 7:15 PM
ft.com logoSummit Therapeutics plc : Holding(s) in Company (LON:SUMM)
announce.ft.com - September 28 at 7:15 PM
schaeffersresearch.com logoBiotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV (LON:SUMM)
www.schaeffersresearch.com - September 26 at 7:33 PM
proactiveinvestors.co.uk logoFTSE 100 slumps 80 points as it waits on US presidential debate (LON:SUMM)
www.proactiveinvestors.co.uk - September 26 at 11:57 AM
nasdaq.com logoMid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss (LON:SUMM)
www.nasdaq.com - September 26 at 11:57 AM
capitalcube.com logoSummit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q2, 2017 By the Numbers : September 15, 2016 (LON:SUMM)
www.capitalcube.com - September 15 at 11:11 AM
publicnow.com logoSummit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community (LON:SUMM)
www.publicnow.com - September 12 at 11:19 AM
globenewswire.com logoSummit Therapeutics plc : Half-yearly report (LON:SUMM)
inpublic.globenewswire.com - September 9 at 11:19 AM
investors.com logoSummit Therapeutics highlights clinical progress (LON:SUMM)
www.proactiveinvestors.com - September 9 at 11:19 AM
finance.yahoo.com logoSummit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016 (LON:SUMM)
finance.yahoo.com - September 5 at 11:23 AM
morningstar.co.uk logoSummit Therapeutics Sees Positive Phase I Trial Results For Ezutromid (LON:SUMM)
www.morningstar.co.uk - August 9 at 10:56 AM
4-traders.com logoSummit Therapeutics : Shows Further Positive Trial Data For Ridinilazole (LON:SUMM)
www.4-traders.com - June 22 at 10:58 AM
investors.com logoSummit uses more than gut instinct to prove C.diff antibiotic's worth (LON:SUMM)
www.proactiveinvestors.com - June 22 at 10:58 AM
publicnow.com logoFirst Quarter Financial Results (LON:SUMM)
www.publicnow.com - June 21 at 12:09 PM
4-traders.com logoSummit Therapeutics : Enrols First Patient In Phase II Ezutromid Trial (LON:SUMM)
www.4-traders.com - June 17 at 10:18 AM
investors.com logoSummit Therapeutics recruits first phase II DMD patient (LON:SUMM)
www.proactiveinvestors.com - June 17 at 10:18 AM

Social

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Summit Therapeutics PLC stock cost?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 190.


Last Updated on 2/19/2017 by MarketBeat.com Staff